Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

INAB

IN8BIO, INC.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • INABIn8bio Inc.
    0Calm

    A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

    Running, no new patientsPhase 1/24 patientsMain results: Dec 2026

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • Quarterly reportQuarterly report (10-Q)Nov 5, 2026
  • Shared quarterly resultsNews report (8-K)Nov 5, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 6, 2026
  • Shared quarterly resultsNews report (8-K)Aug 6, 2026
  • Signed a major agreement; Ended a major agreementNews report (8-K)Jun 1, 2026
  • New shares being soldNew shares being sold (424B5)

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Jun 1, 2026